What Is Epitalon and What the Research Actually Shows

Epitalon is a synthetic peptide made of just four amino acids, and it is best known for one claim, that it can switch on an enzyme called telomerase. That claim has drawn attention, but most of it rests on a small number of cell studies from one research group, plus human studies that tested a different material. This guide explains in plain words what the epitalon peptide is, what benefits have been studied, how it works, whether it has any medical use, what amounts trials used, and what is known about side effects. It describes research only and is not advice for any person.

What Is Epitalon Peptide?

Epitalon, also spelled epithalon, is a tetrapeptide. That means it is a chain of four amino acids, the building blocks of proteins. The order is alanine, glutamate, aspartate, and glycine, often written AEDG. According to Wikipedia, it is a synthetic peptide believed to be the active piece of epithalamin, an extract of the pineal gland. The pineal gland is a small gland deep in the brain that helps control the body clock through the hormone melatonin.

A 2025 review in the International Journal of Molecular Sciences says epitalon was made based on the amino acid makeup of epithalamin, and that its synthesis was patented about 25 years ago. The same review says the peptide was first detected in a natural pineal gland extract in 2017. Most of the research comes from the St. Petersburg Institute of Bioregulation and Gerontology in Russia, led by Vladimir Khavinson, according to Wikipedia.

The table sorts the terms that people often mix up.

Term	What it is	Why it matters
Epitalon	A synthetic four amino acid peptide (AEDG)	The compound most cell studies tested
Epithalamin	An extract of the pineal gland, a mix of many peptides	The material used in most of the long human studies
Telomere	A protective cap at the end of a chromosome	Shortens each time a cell divides
Telomerase	An enzyme that can rebuild telomeres	The target of the epitalon claim

The key distinction is the second row. Epithalamin and epitalon are related, but they are not the same thing, and many of the boldest human results belong to epithalamin.

Epitalon Peptide Benefits Studied in Research

People credit epitalon with many benefits. The list below sorts what has been studied by how well it is supported. Details follow in the sections after it.

Telomere lengthening. Seen in human cells grown in a dish, in 2003, 2004, and 2025 studies. Not confirmed by a large human trial.
Sleep rhythm and melatonin. A small human study reported higher levels of a melatonin by-product in urine. It measured hormones and gene activity, not how well people slept.
Eye health. One report from the original research group, on an inherited eye disease called retinitis pigmentosa, described a positive effect. It needs independent repeat studies.
Antioxidant effects. Lab studies report higher activity of the body’s own antioxidant enzymes. This has not been shown to improve health in people.
Longer life or lower death rates. Reported only for epithalamin, the extract, and only by the group that developed it.
Cancer protection. Not established. Early lab reports suggested fewer tumors in some lab models, but a 2025 cell study also found telomeres lengthening in breast cancer cell lines.

How Epitalon Peptide Works

The best known idea is about telomeres. Think of a telomere as the plastic tip on the end of a shoelace. It keeps the end from fraying. Each time a cell divides, the tip gets a little shorter, and when it becomes too short, the cell stops dividing. This limit is called the Hayflick limit, and it is one reason researchers use telomere length as a marker of cell aging.

Telomerase is an enzyme that can add length back to those tips. Most cells in the body have very little of it. Many cancer cells, on the other hand, need to keep their telomeres long to keep dividing, and they do this either by using telomerase or by a backup route called ALT, short for alternative lengthening of telomeres.

Here is what the studies found.

The 2003 study. The Khavinson group reported in the Bulletin of Experimental Biology and Medicine that adding epithalon to human fetal fibroblast cells, a type of connective tissue cell that was telomerase negative, led to the cells making the working part of telomerase, higher telomerase activity, and longer telomeres.
The 2004 study. Lung fibroblast cells from a 24 week fetus normally lost the ability to divide at the 34th passage, meaning the 34th round of splitting and re-growing the culture. Treated cells had longer telomeres, comparable to those of young cells, and made 10 extra divisions, reaching 44 passages. The authors described this as getting past the Hayflick limit.
The 2025 independent study. Researchers at a UK university tested epitalon in normal epithelial cells, fibroblasts, and two breast cancer cell lines. They reported dose-dependent telomere lengthening in normal cells through higher telomerase activity. In the cancer cells, telomeres also grew, through the ALT route, and the ALT rise was only minor in normal cells. A correction to the paper was published in November 2025. This is a cell-line finding and says nothing direct about people, but it shows why a telomere-lengthening claim cannot be treated as automatically good news.

A second idea is about the body clock. A 2020 paper in Advances in Gerontology reported that the AEDG peptide raised the amount of a melatonin by-product in urine by about 1.7 times and shifted the activity of clock genes in people whose pineal gland function was reduced. A 2020 paper in the journal Molecules proposed that the peptide may also change how genes are switched on, a possible epigenetic mechanism. Lab studies also report more antioxidant enzyme activity, according to Wikipedia.

Even so, the picture is incomplete. The 2025 review says it remains uncertain whether these are the only ways epitalon acts, and that physical and structural studies of the peptide are quite limited.

Current Epitalon Research Areas

Epitalon has no established medical use for any condition, and the research below is early. Three areas have been studied.

Retinitis pigmentosa. A 2002 paper in Neuro Endocrinology Letters from the Khavinson group reported a positive clinical effect in 90 percent of people with degenerative retinal disease. The 2025 review describes a trial of 162 patients that compared treated people with a control group given conventional care of that time. It reported better vision and wider visual fields in treated people. It was run by the same institute that developed the peptide, so independent repeat studies are needed.
Body clock and melatonin. A small human study measured melatonin by-products and clock gene activity, as described above. It did not test sleep quality or any medical outcome.
Aging. The long human studies used epithalamin, not epitalon. A 2003 paper in Neuro Endocrinology Letters described 266 older adults followed for 6 to 8 years, where groups treated with epithalamin had a 1.6 to 1.8-fold lower death rate than the comparison group. A 2006 paper in the Bulletin of Experimental Biology and Medicine described a 12-year randomized study of older people with heart disease, where deaths in the epithalamin group were 28 percent lower. Both come from the group that developed it.

FDA has also addressed epitalon. Its page on bulk drug substances used in compounding lists epitalon among substances that were nominated and later withdrawn by the nominators, having been placed in a category for possible significant safety risks. FDA wrote that it has not found safety information for the route proposed and lacks enough information to know whether the compound would cause harm in humans. The page was current as of April 2026. Questions about regulatory status should go to qualified regulatory or legal advisers.

Epitalon Dosage in Published Research

There is no standard dose. The amounts below are not instructions. They are amounts reported in the research, summarized in the 2025 review, and they apply only to the product, route, and people in each study.

Injected next to the eye. In the retinitis pigmentosa trial, each person received 5.0 micrograms per eye for 10 days in a row.
Under the tongue. In a study of 75 women with placebo and comparison groups, 0.5 mg a day was given for 20 days, and researchers measured melatonin by-products and clock gene activity.
In cell studies. One 2022 study on a human immune cell line tested very small amounts of 0.0025, 0.025, and 0.25 nanograms per milliliter.

The numbers vary widely because the studies asked different questions, used different routes, and tested cells in some cases and people in others. The 2026 review in Frontiers in Aging names optimal dosing regimens and ways to monitor effects as open gaps for epitalon and similar peptides.

Quality is also part of dosing. In 2015, a paper in Drug Testing and Analysis reported finding epitalon in two preparations sold outside regulated channels, products pitched for cancer, old age, and retinitis pigmentosa. What is on the label should be checked. A batch-specific Certificate of Analysis that states identity and purity lets a lab confirm it has what it ordered. The peptide reconstitution guide, the reconstitution ratios guide, and the bacteriostatic water guide cover general laboratory steps.

Epitalon Side Effects in Research

Side effects are not well known. Here is what the sources say.

What was reported. In the 162-patient eye trial, none of the treated people reported side effects. That is a small, short study from the group that developed the peptide, and it was not designed to catch rare or long-term problems.
What has not been studied. The 2026 review in Frontiers in Aging points to a lack of long-term safety data. FDA describes a similar gap.
Possible immune reactions. FDA wrote that compounds like this may pose a risk of immune reactions for certain routes, because peptides can clump together and carry impurities from manufacturing.
The cancer question. Telomere lengthening in cancer cell lines, even through a backup route, is a reason for caution, not a reason for confidence.
Product quality. A product that is not what its label says can cause problems that have nothing to do with epitalon itself.

Because of these gaps, an absence of reported side effects should not be read as proof of safety.

Frequently Asked Questions

What is epitalon peptide?

It is a synthetic tetrapeptide, four amino acids in the order alanine, glutamate, aspartate, and glycine, believed to be the active piece of an extract from the pineal gland.

Is epitalon the same as epithalamin?

No. Epithalamin is the gland extract, a mix of many peptides. Epitalon is the synthetic four amino acid peptide built from the extract’s makeup. Most of the long human studies used epithalamin.

Does epitalon lengthen telomeres?

In cell studies, yes. A 2003 and a 2004 study reported it in human fetal cells, and a 2025 independent study reported it in normal cells and in breast cancer cell lines. No large human trial of the synthetic peptide has confirmed this in people.

Does epitalon slow aging?

That has not been shown. The longest results concern epithalamin, come from one research group, and the reviews call for rigorous validation.

What amounts have been used in studies?

Reported amounts include 5.0 micrograms per eye for 10 days in an eye trial and 0.5 mg a day under the tongue for 20 days in a small study of women. These apply only to those studies and are not guidance.

What side effects have been reported?

None were reported in the 162-patient eye trial, but the studies are small and short. Long-term safety data are lacking, and FDA says it lacks enough information to know whether harm could occur.

Does epitalon have an established medical use?

No medical use has been established, and the research is still early.

Key Takeaways

What it is. Epitalon is a synthetic four amino acid peptide (AEDG) first linked to a pineal gland extract.
How it works. Cell studies from 2003, 2004, and 2025 report more telomerase activity and longer telomeres. A small study also reports effects on melatonin and clock genes.
Benefits. Telomere lengthening is shown in cells only. Other benefits rest on small reports from one group.
Human data. The long human studies used epithalamin, the extract, not synthetic epitalon.
Dosage. Trial amounts apply to the product, route, and people studied and are not guidance.
Side effects. Not well known. No long-term human safety data exist, and the cancer question is open.
Quality. Verify identity and purity with a batch-specific Certificate of Analysis.

Research Use Disclaimer

This content is provided for Research Use Only (RUO). The compounds discussed are not drugs, dietary supplements, foods, or cosmetics, and are not intended for human or animal consumption, diagnostic use, or therapeutic use of any kind. They have not been evaluated by the FDA for safety or efficacy in humans. Any research use must be conducted by qualified professionals in a controlled laboratory environment, in accordance with all applicable institutional, local, and federal regulations.

Sources

Wikipedia contributors. Epitalon. Wikipedia, The Free Encyclopedia.
Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003.
Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004.
Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025.
Correction to, Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025.
Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon, highly bioactive pineal tetrapeptide with promising properties. Int J Mol Sci. 2025.
Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002.
Ivko OM, Linkova NS, Ilina AR, Sharova AA, Ryzhak GA. AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging. Adv Gerontol. 2020.
Khavinson V, Diomede F, Mironova E, et al. AEDG peptide (epitalon) stimulates gene expression and protein synthesis during neurogenesis, possible epigenetic mechanism. Molecules. 2020.
Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003.
Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med. 2006.
Mavrych V, Shypilova I, Bolgova O. Therapeutic peptides in gerontology, mechanisms and applications for healthy aging. Front Aging. 2026.
Vanhee C, Moens G, Van Hoeck E, Deconinck E, De Beer JO. Identification of the small research tetra peptide Epitalon, assumed to be a potential treatment for cancer, old age and Retinitis Pigmentosa in two illegal pharmaceutical preparations. Drug Test Anal. 2015.
U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of April 22, 2026.

Explore the anti-aging research category for related longevity compounds, or view the NAD+ and SS-31 research material. For related reading, see the NAD+ guide, the glutathione guide, and the SS-31 guide.